Search
Patexia Research
Case number 1:19-cv-01498

Boehringer Ingelheim Pharmaceuticals Inc. v. Mankind Pharma Ltd. et al > Documents

Date Field Doc. No.Description (Pages)
Feb 14, 2023 14 PROPOSED CONSENT JUDGMENT Between Boehringer and Mankind and LifeStar Defendants by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc.. (Dellinger, Megan) (Entered: 02/14/2023) (6)
Feb 14, 2023 15 CONSENT JUDGMENT Signed by Judge Colm F. Connolly on 2/14/2023. (nmf) (Entered: 02/14/2023) (6)
Sep 11, 2019 N/A Create Case Association (0)
Docket Text: Case associated with lead case: Create association to 1:18-cv-01689-CFC-SRF. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC ONLY. (nmf)
Sep 11, 2019 13 SO ORDERED (12)
Docket Text: SO ORDERED, re (83 in 1:18-cv-01689-CFC-SRF, 9 in 1:19-cv-01499-CFC, 8 in 1:19-cv-01498-CFC, 8 in 1:19-cv-01494-CFC, 7 in 1:19-cv-01492-CFC, 8 in 1:19-cv-01495-CFC, 8 in 1:19-cv-01501-CFC, 8 in 1:19-cv-01596-CFC, 9 in 1:19-cv-01500-CFC, 9 in 1:19-cv-01493-CFC, 8 in 1:19-cv-01594-CFC, 8 in 1:19-cv-01497-CFC, 7 in 1:19-cv-01496-CFC) STIPULATION Stipulation and [Proposed] Order for Consolidation. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC. Plaintiffs and Defendants shall follow the Scheduling Order entered in the Consolidated Action except for those deadlines outlined in this order. Signed by Judge Colm F. Connolly on 9/9/2019. Associated Cases: 1:18-cv-01689-CFC-SRF et al.(nmf)
Sep 6, 2019 11 Disclosure Statement (1)
Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Lifestar Pharma LLC. (Orlacchio, Adam)
Sep 6, 2019 12 Disclosure Statement (1)
Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Mankind Pharma Ltd.. (Orlacchio, Adam)
Sep 4, 2019 9 Notice of Appearance (1)
Docket Text: NOTICE of Appearance by Adam V. Orlacchio on behalf of Lifestar Pharma LLC, Mankind Pharma Ltd. (Orlacchio, Adam)
Sep 4, 2019 10 Answer to Complaint (19)
Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. by Mankind Pharma Ltd., Lifestar Pharma LLC.(Orlacchio, Adam)
Aug 30, 2019 8 Stipulation (12)
Docket Text: STIPULATION Stipulation and [Proposed] Order for Consolidation by Cipla Limited, Cipla USA, Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc., Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John)
Aug 14, 2019 N/A Case Assigned/Reassigned (0)
Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-01492-CFC et al.(nmg)
Aug 14, 2019 6 Summons Returned Executed (2)
Docket Text: SUMMONS Returned Executed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. Mankind Pharma Ltd. served on 8/14/2019, answer due 9/4/2019. (Dellinger, Megan)
Aug 14, 2019 7 Summons Returned Executed (2)
Docket Text: SUMMONS Returned Executed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. Lifestar Pharma LLC served on 8/14/2019, answer due 9/4/2019. (Dellinger, Megan)
Aug 12, 2019 N/A Summons Issued (0)
Docket Text: Summons Issued with Magistrate Consent Notice attached as to Lifestar Pharma LLC on 8/12/2019; Mankind Pharma Ltd. on 8/12/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (myr)
Aug 9, 2019 1 Main Document (10)
Docket Text: COMPLAINT filed against Lifestar Pharma LLC, Mankind Pharma Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-2705759.) - filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. (Attachments: # (1) Exhibit 1, # (2) Civil Cover Sheet)(myr)
Aug 9, 2019 1 Exhibit 1 (48)
Aug 9, 2019 1 Civil Cover Sheet (1)
Aug 9, 2019 2 Magistrate Consent Forms (3)
Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr)
Aug 9, 2019 3 ANDA Form (1)
Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 3, 2019. Date of Expiration of Patent: April 3, 2034.Thirty Month Stay Deadline: 2/1/2022. (myr)
Aug 9, 2019 4 Patent/Trademark Report to Commissioner (1)
Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,258,637 B2. (myr)
Aug 9, 2019 5 Disclosure Statement (1)
Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. (myr)
Aug 9, 2019 1 Complaint* (1)
Menu